Evidence map›Paper›PMID 39149211›Full record

ArticleFrontiers in microbiology2024

Gut microbe-derived metabolites and the risk of cardiovascular disease in the METSIM cohort.

Sahereh Mirzaei, Holli A DeVon, Rita M Cantor, Arjen Cupido, Lilian Fernandes Silva, Markku Laakso, Aldons J Lusis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sahereh MirzaeiDepartment of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Holli A DeVonSchool of Nursing, University of California, Los Angeles, Los Angeles, CA, United States.
Rita M CantorDepartment of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Arjen CupidoDepartment of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands.
Lilian Fernandes SilvaDepartment of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Markku LaaksoDepartment of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.
Aldons J LusisDepartment of Medicine, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.

Funding

Gut microbiota and metabolite interactions in atherosclerosisR01HL144651 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Aldons Jake Lusis, Federico E Rey · 2021 to 2022
$1.3M
Systems Genetics Dissection of Non-alcoholic SteatohepatitisR01DK117850 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$654k
NHLBI NIH HHS R01 HL144651NHLBI NIH HHS R01 HL148577NIDDK NIH HHS R01 DK117850NINR NIH HHS F32 NR020151
6 · The paper itself

Abstract

Background: An association between gut microbes and cardiovascular disease (CVD) has been established, but the underlying mechanisms remain largely unknown. Methods: We conducted a secondary analysis of the cross-sectional data obtained from the Metabolic Syndrome in Men (METSIM) population-based cohort of 10,194 Finnish men (age = 57.65 ± 7.12 years). We tested the levels of circulating gut microbe-derived metabolites as predictors of CVD, ischemic cerebrovascular accident (CVA), and myocardial infarction (MI). The Kaplan-Meier method was used to estimate the time from the participants' first outpatient clinic visit to the occurrence of adverse outcomes. The associations between metabolite levels and the outcomes were assessed using Cox proportional hazard models. Results: During a median follow-up period of 200 months, 979 participants experienced CVD, 397 experienced CVA, and 548 experienced MI. After adjusting for traditional risk factors and correcting for multiple comparisons, higher plasma levels of succinate [quartile 4 vs. quartile 1; adjusted hazard ratio, aHR = 1.30, (confidence interval (CI), 1.10-1.53) Conclusion: Gut microbe-derived metabolites, succinate, and ursodeoxycholic acid were associated with CVD, MI, and CVA, respectively. Regulating the gut microbes may represent a potential therapeutic target for modulating CVD and CVA.

Indexed as

cardiovascular diseasegut metabolitesmyocardial infarctionstrokesuccinateursodeoxycholic acid

Identifiers

PMID39149211
PMCPMC11324590

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.